2-十四烷氧基硝基苯 | 122329-02-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-十四烷氧基硝基苯
• 中文别名: 邻十四烷氧基硝基苯
• 英文名称: (2-nitro-phenyl)-tetradecyl ether
• 英文别名: (2-Nitro-phenyl)-tetradecyl-aether；1-Nitro-2-(tetradecyloxy)benzene；1-nitro-2-tetradecoxybenzene
• CAS: 122329-02-6
• 化学式: C₂₀H₃₃NO₃
• 分子量: 335.487
• InChiKey: PZZKFDTVGVZNJP-UHFFFAOYSA-N

物化性质

• 沸点：
  443.4±18.0 °C(Predicted)
• 密度：
  0.987±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  24
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2909309090
• 危险性防范说明：
  P302+P352,P337+P313,P304+P340,P312,P280,P332+P313
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-十四烷氧基硝基苯 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 生成 2-十四烷氧基苯胺
  参考文献：
  名称：

  Synthesis and biological evaluation of novel N-(alkoxyphenyl)-aminocarbonylbenzoic acid derivatives as PTP1B inhibitors

  摘要：

  Based on the fact that petroselinic acid showed good inhibitory activity (IC50 = 6.99 mu mol/L) against protein tyrosine phophatase 1B(PTP1B) in vitro, a series of novel N-(alkoxyphenyl)-aminocarbonylbenzoic acid derivatives were designed and synthesized. The results indicated that most of the derivatives showed more potent activities against PTP1B. Especially, compound 13 had obvious activity with an IC50 of 106 nmol/L in vitro. (C) 2010 Song Wu. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2010.07.005
• 作为产物：
  描述：

  十四烷基碘化物 、 银(I)2-硝基苯酚 在 甲苯 作用下， 生成 2-十四烷氧基硝基苯
  参考文献：
  名称：

  Nodzu et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1951, vol. 71, p. 713

  摘要：

  DOI：

文献信息

• N-substituted anilines
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0579066A2

  公开（公告）日：1994-01-19

  57 Compounds of the formula wherein R1 is hydrogen or -(CH2)mCOOR2; R2 is hydrogen, (R6)2N(CH2)2-, R6COOCH2- or -CH2CON(CH2CH20H)2; R3 is hydrogen, nitro, hydroxy, amino, CH3(CH2) nS(O)0-2-, CH3(CH2)n-,CH3(CH2)nO- ,R5COO-, RsOOC- ,R5HNCOO-, RsNHCO-, RsCONH-, RsNHCONH-, [CH3(CH2)n]2NCO- , CH3(CH2)nCHOHCH20-, (2-quinolinyl)methoxy, oleyloxy, linoleyloxy, R8OOC(CH2)t-O, (R6 0)2 PO(CH2)pO- , (HO) (R60)PO(CH2)pO- , R6[O(CH2)2]qO- , R7(CH2)pO-, or -O(CH2)p-pyridinium+(OH-); R4 is CH3(CH2) n- , CH3(CH2)nO- , CF3SO2NH-, RsCOO-, RsOOC- ,R5HNCOO-, RsNHCO-, RsCONH-RsNHCONH-, [CH3(CH2)n]2NCO-, CH3(CH2)nCHOHCH20-, carboxy, (2-quinolinyl)methoxy, oleyloxy, linoleyloxy, R8OOC(CH2)tO-, R6[O(CH2)2]qO- , or R7(CH2)pO-; R5 is CH3(CH2)n-, 1-adamantyl or diphenylmethyl; R6 is lower alkyl; R7 is 1- or 2 -naphthyloxy, 1-, 2- or 3-pyridinyloxy, 2,3- or 3,4-dihydroxyphenyl, 6,7-dihydroxy-2-naphthyl, phenyl, phenoxy or substituted phenyl or phenoxy, wherein the substituent is selected from the group consisting of lower alkyl, lower alkoxy, hydroxy, nitro, amino, halo, R6 S(O)0-2-, carboxy, carboxy-lower alkyl or phenyl; R8 is hydrogen or lower alkyl; n is an integer from 0 to 17; m is an integer from 1 to 3; t is an integer from 1 to 10; p is an integer from 2 to 18, and q is an integer from 1 to 6; and when R2 is hydrogen, a pharmaceutically acceptable salt thereof with a base, are potent inhibitors of phospholipases A2 (PLA2's) and are therefore useful in the treatment of inflammatory diseases, such as psosiasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia/reperfusion, and trauma induced inflammation, such as spinal cord injury.

  57 式中的化合物 式中 R1 是氢或-(CH2)mCOOR2； R2 是氢、(R6)2N(CH2)2-、R6COOCH2- 或-CH2CON(CH2CH20H)2； R3 是氢、硝基、羟基、氨基、CH3(CH2)nS(O)0-2-、CH3(CH2)n-、CH3(CH2)nO-、R5COO-、RsOOC-、R5HNCOO-、RsNHCO-、RsCONH-、RsNHCONH-、[CH3(CH2)n]2NCO-、CH3(CH2)nCHOHCH20-、(2-quinolinyl)methoxy, oleyloxy, linoleyloxy, R8OOC(CH2)t-O, (R6 0)2 PO(CH2)pO-, (HO) (R60)PO(CH2)pO-, R6[O(CH2)2]qO-, R7(CH2)pO-, 或-O(CH2)p-吡啶鎓+(OH-)； R4 是 CH3(CH2)n- ，CH3(CH2)nO- ，CF3SO2NH- ，RsCOO- ，RsOOC- ，R5HNCOO- ，RsNHCO- ，RsCONH-RsNHCONH- ，[CH3(CH2)n]2NCO- 、R8OOC(CH2)tO-、R6[O(CH2)2]qO- 或 R7(CH2)pO-； R5 是 CH3(CH2)n-、1-金刚烷基或二苯基甲基； R6 是低级烷基 R7 是 1-或 2-萘氧基，1-、2-或 3-吡啶氧基，2,3-或 3,4-二羟基苯基，6,7-二羟基-2-萘基，苯基，苯氧基或取代的苯基或苯氧基，其中取代基选自由低级烷基、低级烷氧基、羟基、硝基、氨基、卤代、R6 S(O)0-2-、羧基、羧基-低级烷基或苯基组成的组； R8 是氢或低级烷基； n 是 0 至 17 的整数； m 是 1 至 3 的整数； t 是 1 至 10 的整数； p 是 2 至 18 的整数，和 q 是 1 至 6 的整数； 以及当 R2 为氢时，其与碱的药学上可接受的盐，是磷脂酶 A2（PLA2）的强效抑制剂，因此可用于治疗炎症性疾病，如银屑病、炎症性肠病、哮喘、过敏、关节炎、皮炎、痛风、肺部疾病、心肌缺血/再灌注，以及创伤引起的炎症，如脊髓损伤。
• MAGNESIUM ION SELECTIVE PVC MEMBRANES
  申请人：Radiometer Medical ApS

  公开号：EP3818365A1

  公开（公告）日：2021-05-12
• IMPROVED MAGNESIUM ION SELECTIVE MEMBRANES
  申请人：Siemens Healthcare Diagnostics Inc.

  公开号：US20180024088A1

  公开（公告）日：2018-01-25

  The present invention is directed to membranes, sensors, systems and process for the detection of magnesium ions in protein-containing samples. The novel membranes, sensors, systems, and processes are based upon the discovery that the lipophilcity of the plasticizer (or blend of plasticizers) utilized in the formulation of magnesium ion selective membranes for clinical use is inversely proportional to the sensitivity of the plasticizer(s) and directly proportional to the use life thereof.
• MAGNESIUM ION SELECTIVE MEMBRANES
  申请人：Siemens Healthcare Diagnostics Inc.

  公开号：US20210164931A1

  公开（公告）日：2021-06-03

  The present invention is directed to membranes, sensors, systems and process for the detection of magnesium ions in protein-containing samples. The novel membranes, sensors, systems, and processes are based upon the discovery that the lipophilcity of the plasticizer (or blend of plasticizers) utilized in the formulation of magnesium ion selective membranes for clinical use is inversely proportional to the sensitivity of the plasticizer(s) and directly proportional to the use life thereof.
• [EN] IMPROVED MAGNESIUM ION SELECTIVE MEMBRANES<br/>[FR] MEMBRANES AMÉLIORÉES SÉLECTIVES D'ION MAGNÉSIUM
  申请人：SIEMENS HEALTHCARE DIAGNOSTICS

  公开号：WO2016126593A1

  公开（公告）日：2016-08-11

  The present invention is directed to membranes, sensors, systems and process for the detection of magnesium ions in protein-containing samples. The novel membranes, sensors, systems, and processes are based upon the discovery that the lipophilcity of the plasticizer (or blend of plasticizers) utilized in the formulation of magnesium ion selective membranes for clinical use is inversely proportional to the sensitivity of the plasticizer(s) and directly proportional to the use life thereof.